108 related articles for article (PubMed ID: 2803961)
1. Isotretinoin in the treatment of systemic sclerosis.
Maurice PD; Bunker CB; Dowd PM
Br J Dermatol; 1989 Sep; 121(3):367-74. PubMed ID: 2803961
[TBL] [Abstract][Full Text] [Related]
2. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma.
Krieg T; Langer I; Gerstmeier H; Keller J; Mensing H; Goerz G; Timpl R
J Invest Dermatol; 1986 Dec; 87(6):788-91. PubMed ID: 3782862
[TBL] [Abstract][Full Text] [Related]
3. Skin scoring in systemic sclerosis: a modification--relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP).
Zachariae H; Bjerring P; Halkier-Sørensen L; Heickendorff L; Søndergaard K
Acta Derm Venereol; 1994 Nov; 74(6):444-6. PubMed ID: 7701875
[TBL] [Abstract][Full Text] [Related]
4. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma.
Majewski S; Skiendzielewska A; Makieła B; Jablońska S; Błaszczyk M
Arch Dermatol Res; 1987; 279(7):484-6. PubMed ID: 3435177
[No Abstract] [Full Text] [Related]
6. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
Scheja A; Hellmer G; Wollheim FA; Akesson A
Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
[TBL] [Abstract][Full Text] [Related]
7. Photopheresis in systemic sclerosis: clinical and serological studies using markers of collagen metabolism.
Zachariae H; Bjerring P; Heickendorff L; Møller B; Wallevik K; Angelo H
Acta Derm Venereol; 1993 Oct; 73(5):356-61. PubMed ID: 7904402
[TBL] [Abstract][Full Text] [Related]
8. Plasma endothelin and the aminoterminal propeptide of type III procollagen (PIIINP) in systemic sclerosis.
Zachariae H; Heickendorff L; Bjerring P; Halkier-Sørensen L; Søndergaard K
Acta Derm Venereol; 1994 Sep; 74(5):368-70. PubMed ID: 7817674
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.
Black CM; Silman AJ; Herrick AI; Denton CP; Wilson H; Newman J; Pompon L; Shi-Wen X
Arthritis Rheum; 1999 Feb; 42(2):299-305. PubMed ID: 10025924
[TBL] [Abstract][Full Text] [Related]
10. Type III collagen aminopropeptide and laminin P1 levels in serum of patients with silicosis-associated and idiopathic systemic scleroderma.
Herrmann K; Schulze E; Heckmann M; Schubert I; Meurer M; Ziegler V; Haustein UF; Mehlhorn J; Krieg T
Br J Dermatol; 1990 Jul; 123(1):1-7. PubMed ID: 2117968
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen.
Kucharz EJ; Jonderko G; Rubisz-Brzezinska J; Brzezinska-Wcisło L
Clin Rheumatol; 1995 May; 14(3):380-1. PubMed ID: 7641522
[No Abstract] [Full Text] [Related]
12. Isotretinoin and curly hair.
Bunker CB; Maurice PD; Dowd PM
Clin Exp Dermatol; 1990 Mar; 15(2):143-5. PubMed ID: 2347106
[TBL] [Abstract][Full Text] [Related]
13. Effects of systemic isotretinoin on serum markers of collagen synthesis and degradation.
Autio P; Risteli J; Palatsi R; Väänänen K; Vuori J; Risteli L; Oikarinen A
Acta Derm Venereol; 1993 Apr; 73(2):108-12. PubMed ID: 8103253
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity.
Cozzi F; Marson P; Rosada M; De Silvestro G; Bullo A; Punzi L; Todesco S
Transfus Apher Sci; 2001 Aug; 25(1):25-31. PubMed ID: 11791759
[TBL] [Abstract][Full Text] [Related]
15. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.
Zachariae H; Halkier-Sørensen L; Heickendorff L
Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612
[TBL] [Abstract][Full Text] [Related]
16. Low-dose methotrexate in the treatment of widespread morphea.
Seyger MM; van den Hoogen FH; de Boo T; de Jong EM
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):220-5. PubMed ID: 9704833
[TBL] [Abstract][Full Text] [Related]
17. Isotretinoin and lung function in systemic sclerosis.
Bunker CB; Maurice PD; Little S; Johnson NM; Dowd PM
Clin Exp Dermatol; 1991 Jan; 16(1):11-3. PubMed ID: 2025925
[TBL] [Abstract][Full Text] [Related]
18. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma.
Diot E; Diot P; Valat C; Boissinot E; Asquier E; Lemarie E; Guilmot JL
Eur Respir J; 1995 Sep; 8(9):1559-65. PubMed ID: 8575585
[TBL] [Abstract][Full Text] [Related]
20. Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect.
Autio P; Oikarinen A; Melkko J; Risteli J; Risteli L
Br J Dermatol; 1994 Nov; 131(5):660-3. PubMed ID: 7999597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
